Trending Tickers: $CRWE Up on Nvidia Bet, $QBTS Launches New System, $REGN Acquires 23andMe
This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
CoreWeave ($CRWE) Jumps After Nvidia Discloses $896M Stake
CoreWeave ($CRWE), the GPU-focused cloud infrastructure company, soared this week after Nvidia ($NVDA) disclosed a massive new stake in the company. In its Q1 2025 13F filing, Nvidia revealed ownership of approximately 24.2 million CoreWeave shares—roughly 7% of the company’s outstanding stock—valued at $896 million as of March 31. This makes CoreWeave the largest single holding in Nvidia’s investment portfolio.
CoreWeave, which went public in March at $40 per share, provides GPU-accelerated cloud computing services and is tightly integrated with Nvidia hardware. The company reported a 420% year-over-year revenue increase in Q1, driven by growing demand for AI model training and inference. The partnership and Nvidia’s backing position CoreWeave as a major player in the AI infrastructure space.
Stock Price Movement
$CRWE jumped 22% following Nvidia’s filing and continued to climb, rising from $66 to over $100 per share in the days that followed.
D-Wave ($QBTS) Rolls Out New Quantum System
D-Wave Quantum Inc. ($QBTS) has launched its latest quantum computer, the Advantage2 system, which the company says is its most advanced and powerful to date. According to D-Wave, this sixth-generation machine is now available to customers and is designed to handle real-world problems in areas like logistics, materials science, and artificial intelligence—tasks that are difficult for traditional computers to solve.
The Advantage2 features over 4,400 superconducting qubits and builds on years of development in quantum annealing, a technique used for solving complex optimization problems. The company says the new system delivers major improvements over the previous generation, including:
- 40% increase in energy scale
- 75% reduction in noise, leading to more accurate results
- Double the coherence, helping solve problems faster
- 20-way qubit connectivity, allowing more complex problem structures to be processed
The system is now accessible via Leap, D-Wave’s cloud service, which the company says is available in over 40 countries and offers enterprise-grade uptime and security. For customers with specialized needs, the Advantage2 can also be installed on-premises. One installation is already planned at Davidson Technologies in Alabama for national security-related research.
According to D-Wave, usage of Advantage2 prototypes has surged recently, with customer problem-solving activity up 134% in the past six months. More than 20 million problems have been run using the system since 2022.
Stock Price Movement
$QBTS shares surged 26% following the announcement of the Advantage2 system launch.
Regeneron ($REGN) to Acquire Bankrupt 23andMe for $256M
Regeneron Pharmaceuticals ($REGN), a U.S.-based biotech company known for its genetics-driven approach to drug development, has announced an agreement to acquire substantially all assets of bankrupt consumer genetics firm 23andMe. The $256 million deal, resulting from a bankruptcy auction, includes the company’s Personal Genome Service®, Total Health and Research Services, and Biobank operations. The transaction is subject to court and regulatory approvals and is expected to close in Q3 2025.
According to Regeneron, the acquisition aligns with its long-standing investment in genetics to support research and treatment innovation for serious diseases. The company emphasized its commitment to upholding 23andMe’s privacy policies and said it is prepared to work with a court-appointed Customer Privacy Ombudsman to review its data use and privacy safeguards.
- Strategic Fit: Regeneron stated the acquisition supports its mission of improving health outcomes through large-scale genetic research, enhancing its ability to translate insights into new therapies.
- Data Protection: The company pledged to uphold existing privacy protections and laws, underscoring its experience handling de-identified genetic data from millions of research participants.
- Consumer Services to Continue: 23andMe will continue operating as a wholly owned subsidiary, offering consumer genome services without interruption.
- Excludes Lemonaid Health: The transaction does not include 23andMe’s telehealth platform, Lemonaid Health.
Regeneron said the move would help preserve 23andMe’s platform while integrating it into Regeneron’s broader efforts to use genetic insights to advance public health. The deal highlights continued consolidation in the genetics space and underscores the value of direct-to-consumer data in future drug discovery.
Stock Price Movement
$REGN stock saw a modest uptick in the days following the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
